在晚期黑色素瘤中ICI治疗失败后的向治疗和PARPi治疗反应:一个病例系列
George Nassief1, Renee Morecroft2, Jordan Phillipps3
1Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO, USA.
Melanoma management
|December 9, 2025
概括
多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 在晚期黑色素瘤治疗中表现有前途. 将PARPi与免疫检查点抑制剂和向疗法结合起来,在同源重组缺乏症患者中产生了持久的反应.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 黑色素瘤治疗方法
背景情况:
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 在同源重组缺陷 (HRD) 癌症中有效.
- 目前尚不清楚PARPi与标准黑色素瘤治疗的协同作用.
研究的目的:
- 研究在晚期转移性黑色素瘤中将PARPi与免疫检查点抑制剂 (ICI) 和BRAF/MEK抑制剂结合使用的疗效.
- 探索PARPi与其他黑色素瘤疗法之间的潜在协同机制.
主要方法:
- 关于两名患有晚期转移性黑色素瘤,不耐标准治疗的患者的病例报告.
- 治疗涉及组合疗法,包括PARPi,ICI和BRAF/MEK抑制剂.
- 对同源重组修复 (HRR) 途径突变和治疗结果的分析.
主要成果:
- 两位患者都实现了持久的部分反应,无进展生存时间超过11个月.
- 患者患有HRR通路突变,并且能够很好地容忍组合疗法.
- 机制可能涉及PARPi通过cGAS-STING通路和PD-L1调制增强免疫性.
结论:
- PARPi组合疗法显示了晚期黑色素瘤的潜力,特别是在HRD瘤中.
- 这些发现支持进一步的临床试验,用于治疗黑色素瘤中基于PARPi的组合.
- 最佳的序列和组合需要进一步研究.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K